Zeltia Achieves Consolidated EBITDA Break-Even in 1Q10

Yondelis(R) sales increased by 110% with respect to 1Q09

MADRID, April 29, 2010 - Consolidated revenues for Zeltia (ZEL.MC) amounted to 32.9 million euro
in 1Q10, up 49% with respect to 1Q09. Net income improved 50%.

Net revenues in biopharmaceuticals rose 90.9%, primarily due to
Yondelis(R) sales, which totalled 16.6 million euro in the first quarter.
Almost 60 countries worldwide have authorised the sale of Yondelis(R).

Genómica increased total sales by 29.5% to 1.8 million euro.

Consumer chemical sales amounted to 14.3 million euro, an increase of
16.5% compared with 1Q09, despite the adverse economic situation, which has
affected spending.

The company reached EBITDA break-even (68 thousand euro). EBITDA in 1Q09
was -1.1 million euro despite including 7.8 million euro in revenues for
licensing Yondelis(R) to Taiho Pharmaceutical Co. in Japan.

The bottom line reflects a 50% improvement in losses (-1.96 million euro
in 1Q10, compared with -3.91 million euro in 1Q09).

The Group's net cash position (cash + cash equivalents - short-term bank
debt) amounted to 25.2 million euro.

About Zeltia:

Zeltia S.A. is a world-leading biopharmaceutical company specialised in
the development of marine-based drugs for use in oncology and central nervous
system illnesses. Grupo Zeltia consists mainly of the following companies:
PharmaMar, the world-leading biotechnology company in advancing cancer care
through the discovery and development of innovative marine-derived medicines;
Noscira, a biotech firm focused on discovering and developing new drugs
against Alzheimer's disease and other neurodegenerative central nervous
system diseases; Genómica, Spain's leading molecular diagnostics company;
Sylentis, dedicated to researching therapeutic applications of gene silencing
(RNAi); and a chemical division comprising Zelnova and Xylazel, two highly
profitable companies that are leaders in their respective market segments.

    For information:
    Tel. +34-91-444-45-00

    Capital Markets Department
    José Luis Moreno
    Florencia Radizza

    Media relations
    Fernando Mugarza

This press release is also available in the Current events section on
Zeltia's web site: www.zeltia.com

Capital Markets Department: José Luis Moreno or Florencia Radizza; or Media relations: Fernando Mugarza, Tel. +34-91-444-45-00